

Genomma Lab Internacional S.A.B. DE C.V. Fourth Quarter & Full Year 2021 Earnings Call

Presenters: Mr. Jorge Luis Brake, Chief Executive Officer
Mr. Antonio Zamora, Chief Financial Officer

Date: Thursday, February 24, 2022

Time: 11:00 a.m. ET / 10:00 a.m. CST (Mexico City Time)

Dial-in: +1 877-407-0784 (U.S.)
+1 201-689-8560 (International)
If you would prefer to receive a call rather than dialing in, please register via the following link. Please use this option 10-15 minutes prior to conference call start time: [Call Me Link](#)

Participants who do not wish to be interrupted to have their information gathered may have provider dial out to them by clicking on the above link, filling in the information, and pressing the green phone button at the bottom. The phone number provided will be automatically called and connected to the conference without any interruption to the participant. (Please note: Participants will be joined directly to the conference and will hear hold music until the call begins. No confirmation message will be played when joined.)

Webcast: [Fourth Quarter & Full Year 2021 Results](#)

Replay: +1 844-512-2921 (U.S.)
+1 412-317-6671 (International)
Replay ID: 13726888
**Available until March 3, 2022

Note: Genomma Lab will report Fourth Quarter & Full Year 2021 Earnings Release on Wednesday, February 23, 2022 after the Mexican Market (BMV) close.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "**LABB**" (Bloomberg: **LABB:MM**).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.